Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029495 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
A Phase 3 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT02029495: Clinical Trial Phase 3 study, sponsored by Bausch Health Americas.
NCT02029495 is a Phase 3 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 478 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02029495, a Phase 3 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
Primary Outcome
An ACR20 response is defined as at least 20% improvement of tender and swollen joint counts combined with at least 20% improvement in at least 3 of the following 5 parameters: Patients Global Assessment, PtGA of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either Erythrocycte sedimentation rate (ESR) or C-Reactive protein (CRP) (ACR components).
Interventions
- DRUG Placebo
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Why NCT02029495 stopped before completion
NCT02029495 is an interventional study that assigns participants to a tested intervention. The registered 478 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02029495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02029495 about?
NCT02029495 is a clinical study titled "Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis". The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
What is the current status of trial NCT02029495?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2014-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02029495?
The interventions under investigation include: Placebo (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT02029495?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02029495's enrollment target sits among peer trials
478 805th of 2000 higher than 1,194 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia